


AUTHOR QUERY FORM

 ELSEVIER	Journal: PUHE Article Number: 2253	Please e-mail your responses and any corrections to: E-mail: corrections.esco@elsevier.tnq.co.in
------------------------------------------------------------------------------------------------------	---------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

Location in article	Query / Remark: Click on the Q link to find the query's location in text Please insert your reply or correction at the corresponding line in the proof
Q1	Highlights should only consist of "125" characters per bullet point, including spaces. The highlights provided are too long; please edit them to meet the requirement. Also note that Highlights should consist of 3-5 bullet points. There are 6 bullet points provided. Please edit the highlights to meet the requirement.
Q2	Please note that as per journal style 'First person usage (text 'we', 'I' etc.) should be reworded'. Hence the language in this paper has been slightly changed. Kindly check for clarity of thought, and that the meaning is still correct, and amend if necessary.
Q3	Please check the section Author statements, and correct if necessary.
Q4	Please provide the volume number or issue number or page range for the bibliography in Refs. 1, 10.
Q5	'et al.' is not allowed as per the journal style. Please list all author names in Ref. 3, 4, 10.
Q6	Please confirm that given names and surnames have been identified correctly.
Q7	<p>Your article is registered as a regular item and is being processed for inclusion in a regular issue of the journal. If this is NOT correct and your article belongs to a Special Issue/Collection please contact j.holdridge@elsevier.com immediately prior to returning your corrections.</p> <div data-bbox="304 1591 895 1770" style="border: 1px solid black; padding: 5px;"> <p>Please check this box or indicate your approval if you have no corrections to make to the PDF file</p> <div style="text-align: right;"> <input data-bbox="791 1651 876 1732" type="checkbox"/> </div> </div>

Thank you for your assistance.

Available online at www.sciencedirect.com

Public Health

journal homepage: www.elsevier.com/puhe

Highlights

- Whole Body Vibration (WBV) has been exhibited to be effective as a co-adjuvant treatment for type 2 diabetes patients (T2DM) patients in primary care.
- There are no published studies on the cost-effectiveness assessment of WBV in primary care.
- The randomized controlled trial reports the cost-effectiveness of a 12-week WBV.
- In the base-case analysis, whole body vibration has been shown to be cost-effective as co-adjuvant when compare with the standard care alone in T2DM patients.
- The robustness of the cost-utility analysis was confirmed with two other possible scenarios.
- The results from this report could help in the decision process of adding this therapy to the standard care for people who suffer from type 2 diabetes.

01



ELSEVIER

Available online at www.sciencedirect.com

Public Health

journal homepage: www.elsevier.com/puhe

Short Communication

Cost-utility analysis of a 12-week whole-body vibration based treatment for people with type 2 diabetes: reanalysis of a RCT in a primary care context

R.M. Alfonso-Rosa^a, J. del Pozo-Cruz^a, B. del Pozo-Cruz^{b,*},
B. Sañudo Corrales^a, J.M. Abellán-Perpiñán^c

^a Department of Physical Education and Sport, Faculty of Education, University of Seville, C/Pirotecnia s/n, 41013 Seville, Spain

^b Department of Sport and Exercise Science, The University of Auckland, 261 Morrin Rd., St Johns, 1072 Auckland, New Zealand

^c Department of Applied Economics, Faculty of Economics and Business, University of Murcia, Campus de Espinardo s/n, 30100 Murcia, Spain

ARTICLE INFO

Article history:

Received 15 July 2014

Received in revised form

6 January 2015

Accepted 22 February 2015

Available online xxx

Introduction

Along with nutrition, exercise has long been recognized as a cornerstone for Type 2 Diabetes (T2DM) management in both primary and secondary prevention. Whole-body vibration (WBV) training, a relatively new exercise modality, has been previously tested in different clinical populations with promising results. One of the strengths of this exercise modality is the reduced time and conscious process required to be applied. The research group has previously demonstrated that the addition of a short-term (i.e. 12-wk) WBV-based

therapy in a primary care context is feasible, safe and effective to clinically reduce HbA1c and fasting blood glucose, and to improve cardiovascular risk factors in previously sedentary people with T2DM.¹

Nonetheless, these programs must be considered under limited health system resources. Policy makers frequently select the treatment strategies based on their cost per quality of life-adjusted life-year (QALY), called cost-utility, representing the ratio of the QALYs gained divided by incremental cost of the new treatment compared to another (e.g. standard care). Cost-utility analysis allows health interventions, within and across health care programs, to be compared in terms of their cost and the number of QALYs they offer, thereby permitting finite health care resources to be allocated on a utilitarian 'cost per QALY gained' basis.

Different lifestyle modification programs have showed an acceptable cost-utility ratio.^{2,3} Also exercise, resistance, aerobic or combined has showed to be cost-effective among T2DM patients after six month.⁴ Unfortunately, there are no studies analysing the cost-effectiveness of WBV-based exercise programs for patients with T2DM. Researchers therefore aimed in this report to conduct an economic evaluation of the

* Corresponding author. Tel.: +64 9 373 7599x86990.

E-mail address: b.delpozocruz@auckland.ac.nz (B. del Pozo-Cruz).
<http://dx.doi.org/10.1016/j.puhe.2015.02.025>

0033-3506/© 2015 Published by Elsevier Ltd on behalf of The Royal Society for Public Health.

addition to the standard care of a 12-week of a WBV therapy for sedentary older adults with T2DM. In doing so, the data from a previous randomized controlled trial have been used.¹

The study procedures are described elsewhere.¹ All participants signed an informed consent form prior to participation in the study. Participants in the study were recruited via health care staff from a primary care center in Seville, Spain. Fifty patients fulfilled the inclusion/exclusion criteria¹ and were allocated at random to one of the two study group (intervention or control). Participants in both the intervention and control groups had access to the standard care (consisting on outpatient visit for the control of the diabetes-related parameters and on giving advices to improve it – i.e. healthy lifestyle advice including exercise and diet). Participants in the intervention group participated in a 12-week WBV-based program on an oscillating platform (Physio Wave 700, Globus, Italy) consisting of three sessions per week with at least one day between sessions. Each exercise session was performed with a frequency ranging from 12 Hz (first month) to 16 Hz (last month) and a peak-to-peak displacement of 4 mm that was maintained during the entire program. Participants adopted an isometric squat position during all exposures, with knees flexed at 100° for 30 s. After that, participants were asked to perform eight exercises (lunge, step up and down, squat, calf raises, left and right pivot, shoulder abduction with elastic bands, shoulder abduction with elastic bands while squatting, arm swinging with elastic bands) with slow movements at a rate of 3 s for both concentric and eccentric phases. The duration of the sets was progressively increased (30–60 s) with rest periods of 30 s. More details about the performed WBV-based exercise program are published elsewhere.¹

Cost-utility analysis results

The 6-dimensional Short-Form 6D (SF-6D) utility index⁵ was calculated according to the Spanish tariff proposed by Abellán-Perpiñán et al.⁶ Unit costs of the intervention were also recorded. Since societal costs could be considered insignificant for this trial (all participants lived around the area where the intervention was performed and the time for training was of convenience for participants), the chosen perspective for the economic analysis was the health system perspective. Costs in this study were focused on the duration of the program (three months) so no adjustment or discounting was made. No extra costs were computed for room facilities (as the room was facilitated by the primary care center) and no extra costs were computed for recruiting participants (as practitioners did not need any extra time to do it). No further costs from consultation or medication were computed as no statistically significant differences were found between groups. Costs were therefore recorded in Euros based on the salary of the technician for the three months period (i.e. €1800) and the price of the vibratory device (i.e. €5000).

SF-6D utility index was transformed in QALYs by using the area under the curve method.⁷ The incremental cost-effectiveness ratio (ICUR) was calculated as the incremental cost of WBV intervention divided by the difference in QALYs

between the groups. The 95% confidence interval of incremental QALYs between groups and ICUR were calculated using non-parametric bootstrapping technique and plotted a cost effectiveness acceptability curve with the main aim of calculating the probability that the intervention is cost effective.⁸ Although there is not an official cost per QALY threshold in Spain (i.e. a cut-off point below which a health technology represents good value for money), empirical estimations range from €6985 to €53,454/QALY,^{9–11} so it has been decided to take the midpoint €23,235 as the benchmark according to which assessing whether the treatment is cost-effective or not.

In the trial, the mean incremental cost per participant was €272 [i.e. intervention group incremental cost (€6800) divided by the number of participants allocated to the intervention group ($n = 25$)]. The incremental QALY was 0.075 (95%CI 0.006–0.10) in favour of the intervention group. The ICUR was therefore 3626.661 (95%CI 2247.933 to 12952.381). Additionally, two sensitivity analyses were performed assuming the following: a) sport technician salary 30% lower and 30 participants in the intervention (best case scenario) and b) sport technician salary 30% higher and 15 participants in the intervention (worst case scenario). The estimated cost utility ratios were €3226.667/QALY of the best scenario and €7413.334/QALY of the worst scenario. The cost-effectiveness acceptability curve (Fig. 1) showed 99% probability that the addition of the WBV-based program to the standard care is an acceptable strategy if the ceiling of inversion is €23,235/QALY.

The current study is, to the knowledge, the first cost-utility analysis of a WBV-based exercise program for type 2 diabetes patients in a primary care context. In a previous report on the original randomized controlled trial¹ it have been shown that this therapy is effective to improve the functionality and the illness process among a group of volunteers with type 2 diabetes. The main findings of the current analysis of the trial were that the intervention was cost-effective in terms of cost per QALYs when compared with the standard care.

The current study shows 99% of probability of cost-effectiveness using €23,235 per QALY as a threshold. This intervention would be cost-effective even using other commonly threshold used in the Western countries and Unites States. Moreover, the calculated gained QALYs of 0.075 with WBV-based therapy in addition to the standard care as compared with only the standard care was acceptable in comparison with the threshold for minimally important differences (i.e. 0.011–0.097 QALY).¹²




Fig. 1 – The cost-effectiveness acceptability curve.

Extensive sensitive analysis showed that the above commented findings were robust under different assumptions regarding the salary of the sport technician and the people enrolled in the program. When the best scenario was simulated a more attractive incremental cost-utility ratios was achieved. On the other hand, when the worst case scenario (sport technician salary 30% higher and 15 participants in the intervention) was assumed the intervention was still shown to be cost-effective.

In conclusion, the current study shows that the addition of a short-term (i.e. 12-wk) WBV-based exercise program to the standard care is cost-effective as compare with the standard care. Future studies are warranted to confirm the long term effectiveness and cost-effectiveness of this kind of therapies among type 2 diabetes patients.

Implications for practice

The current study has several implications for diabetes education and health promotion programs. Exercise has been extensively reported as key component in the treatment of diabetes. Nonetheless, these programs must be considered under limited health system resources. This study demonstrates that a WBV-based therapy in a primary care context is cost-effective. The exercise programme showed here could be directly applied in other primary care facilities. Therefore, the results from this report could help in the decision process of adding this therapy to the standard care for people who suffer from type 2 diabetes.

Author statements

Acknowledgements

The authors, would like to thank A.C., S.C., A.F. and M.H. for their technical contribution to the study. Also, the authors would like to thank the staff from the primary care center 'Los Bermejales' (Seville, Spain) for their contribution in the recruitment process of patients included in the study and for providing the facility for testing. The authors also thank J.R., M.C. and C.C. for institutional support.

Ethical approval

The study was approved by the research ethics committee of the University of Seville and conducted in accordance with the Declaration of Helsinki, as revised in Edinburgh, 2008.

Funding

None declared.

Competing interests

The authors declare that they do not have any conflict of interests.

REFERENCES

1. del Pozo-Cruz B, Alfonso-Rosa R, del Pozo-Cruz J, Sañudo B, Rogers ME. Effects of a 12-wk whole-body vibration based intervention to improve type 2 diabetes. *Maturitas*; 2013.
2. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson EB, Osterlind J, Eliasson M. Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. *Arch Intern Med* 2010;**170**(16):1470–9.
3. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann Intern Med* 2005;**142**(5):323–32.
4. Coyle D, Coyle K, Kenny GP, Boulé NG, Wells GA, Fortier M, et al. Cost-effectiveness of exercise programs in type 2 diabetes. *Int J Technol Assess Health Care* 2012;**28**(3):228–34.
5. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *J Health Econ* 2002;**21**(2):271–92.
6. Abellan Perpignan JM, Sánchez-Martínez F, Martínez Pérez F, Méndez I. Lowering the 'floor' of the SF-6D scoring algorithm using a lottery equivalent method. *Health Econ* 2012;**21**(11):1271–85.
7. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. *Value Health* 2005;**8**(5):521–33.
8. Willan AR. On the probability of cost-effectiveness using data from randomized clinical trials. *BMC Med Res Methodol* 2001;**1**:8.
9. Pinto JL, Rodríguez R. ¿Cuánto vale la pena gastarse para ganar un año de vida ajustado por calidad? Un estudio empírico. In: Puig J, Pinto JL, Dalmau, editors. *El valor monetario de la salud*. Barcelona: Springer-Verlag; 2001.
10. Abellán JM, et al. El valor monetario de una víctima no mortal y del año de vida ajustado por la calidad. 2011 (mimeo). *Estimación el contexto los Accid tráfico*; 2011.
11. Pinto JL, Martínez JE. Estimación del valor monetario de los años de vida ajustados por calidad: estimaciones preliminares. *Ekonomiaz* 2005;**13**(60):193–209.
12. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res* 2005;**14**(6):1523–32.